Envestnet Asset Management Inc. Boosts Holdings in BioNTech SE (NASDAQ:BNTX)

Envestnet Asset Management Inc. grew its stake in shares of BioNTech SE (NASDAQ:BNTX – Get Rating) by 32.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 19,450 shares of the company’s stock after purchasing an additional 4,742 shares during the period. Envestnet Asset Management Inc.’s holdings in BioNTech were worth $2,623,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Captrust Financial Advisors boosted its position in BioNTech by 6.9% during the 2nd quarter. Captrust Financial Advisors now owns 1,068 shares of the company’s stock valued at $159,000 after acquiring an additional 69 shares in the last quarter. Centaurus Financial Inc. boosted its position in shares of BioNTech by 5.2% during the first quarter. Centaurus Financial Inc. now owns 1,448 shares of the company’s stock valued at $247,000 after purchasing an additional 71 shares in the last quarter. Midwest Professional Planners LTD. grew its stake in BioNTech by 6.0% in the third quarter. Midwest Professional Planners LTD. now owns 1,885 shares of the company’s stock worth $254,000 after purchasing an additional 106 shares during the period. First Republic Investment Management Inc. raised its holdings in BioNTech by 1.8% in the second quarter. First Republic Investment Management Inc. now owns 6,793 shares of the company’s stock worth $1,013,000 after purchasing an additional 117 shares in the last quarter. Finally, Foster & Motley Inc. lifted its position in BioNTech by 4.6% during the third quarter. Foster & Motley Inc. now owns 3,246 shares of the company’s stock valued at $438,000 after buying an additional 144 shares during the period. Hedge funds and other institutional investors own 15.29% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently issued reports on BNTX. Berenberg Bank set a $300.00 price target on shares of BioNTech in a research note on Monday, January 30th. TheStreet raised BioNTech from a “c+” rating to a “b-” rating in a research report on Wednesday, February 1st. The Goldman Sachs Group reduced their price objective on BioNTech from $177.00 to $156.00 and set a “neutral” rating for the company in a research report on Tuesday, January 31st. Morgan Stanley boosted their target price on BioNTech from $203.00 to $216.00 and gave the stock an “equal weight” rating in a report on Tuesday, January 24th. Finally, JPMorgan Chase & Co. reduced their price target on BioNTech from $148.00 to $142.00 and set a “neutral” rating for the company in a report on Wednesday, February 8th. Five equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $206.69.

BioNTech Stock Down 0.1 %

BNTX opened at $128.88 on Thursday. The stock has a market capitalization of $31.28 billion, a price-to-earnings ratio of 2.91 and a beta of 0.24. The firm has a 50 day moving average price of $141.41 and a 200-day moving average price of $147.04. BioNTech SE has a twelve month low of $117.08 and a twelve month high of $189.07. The company has a quick ratio of 5.30, a current ratio of 5.37 and a debt-to-equity ratio of 0.01.

About BioNTech

(Get Rating)

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer.